Dublin, Feb. 27, 2019 (GLOBE NEWSWIRE) -- The "2019 Future of Rosacea R&D Pipeline Drugs and Companies- Analysis of Global Rosacea Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments" report has been added to ResearchAndMarkets.com's offering.

The global demand for Rosacea treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Rosacea pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Rosacea pipeline companies from advancing their products into Phase 3 or Phase 4.

Rosacea Report Description

The pipeline review report on Rosacea pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Rosacea pipeline compounds.

The Rosacea pipeline guide presents information on all active drugs currently being developed for Rosacea. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Rosacea pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Rosacea drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Rosacea product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Rosacea pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Scope of Rosacea pipeline report includes

• An overview of Rosacea disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of pipeline compounds
• Company wise list of pipeline compounds
• Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided

• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials

Reasons to Buy

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Rosacea pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Rosacea pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into the market through in-depth strategic analysis review
• Know the list of companies participating in global Rosacea pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Key Topics Covered:

1. List of Tables & Figures

2. Global Rosacea Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. Executive Summary
3.1 Rosacea Drugs under active development, H1-2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Rosacea pipeline, H1-2019
3.5 Mechanism of Action wise Rosacea Pipeline Candidates

4. Accuitis Rosacea Pipeline Details
4.1 Accuitis Business Profile
4.2 Accuitis Rosacea Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. Accuitis Pharmaceuticals Inc Rosacea Pipeline Details

6. Afecta Pharmaceuticals Inc Rosacea Pipeline Details

7. AOBiome LLC Rosacea Pipeline Details

8. BioPharmX Inc Rosacea Pipeline Details

9. Cellix Bio Pvt Ltd Rosacea Pipeline Details

10. Cutanea Life Sciences Inc Rosacea Pipeline Details

11. Dermata Therapeutics LLC Rosacea Pipeline Details

12. Emeriti Pharma AB Rosacea Pipeline Details

13. Foamix Pharmaceuticals Ltd Rosacea Pipeline Details

14. Hovione Rosacea Pipeline Details

15. Matrisys Bioscience Inc Rosacea Pipeline Details

16. PHI Therapeutics Inc Rosacea Pipeline Details

17. Promius Pharma LLC Rosacea Pipeline Details

18. Sol-Gel Technologies Ltd Rosacea Pipeline Details

19. Sunny Pharmtech Inc Rosacea Pipeline Details

20. TWi Biotechnology Inc Rosacea Pipeline Details

20. Latest Rosacea Drug Pipeline Developments, 2019

21. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/r2n352/rosacea_randd?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Clinical Trials, Dermatological Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.